Human dendritic cells (DC) can be differentiated from blood monocytes in the presence of GM-CSF and IL-4 and matured by lipopolysaccharide (LPS). Vitamin D 3 inhibits the maturation of human DC measured by changes in surface expression of HLA-DR, CD14, CD40, CD80, CD83, and CD86. We here examine the function of vitamin D 3 during DC maturation. One of the earliest changes to LPS-induced maturation was an increase in CD83 expression. Vitamin D 3 inhibited the increase in expression of HLA-DR, CD40, CD80, CD83, and CD86 and the decrease in expression of CD14, which was paralleled morphologically by vitamin D 3 -induced inhibition of dendritic cell differentiation. Vitamin D 3 acted in synergy with the TLR agonists LPS and peptidoglycan (PGN) in inducing IL-6, IL-8, and IL-10, whereas vitamin D 3 completely inhibited LPS-induced secretion of IL-12. The synergy occurred at concentrations where neither vitamin D 3 nor the TLR agonists alone induced measurable cytokine secretion. Both LPS and PGN enhanced the level of the vitamin D 3 receptor (VDR). Taken together, these data demonstrated that vitamin D 3 and TLR agonists acted in synergy to alter secretion of cytokines from human DC in a direction that may provide an anti-inflammatory environment.
Introduction
Dendritic cells (DC) are highly specialized, professional antigen-presenting cells (APC) that orchestrate the immune response via integration of a variety of signals [1] . Immunosuppressive and anti-inflammatory compounds like IL-10 [2], 1 ,25-dihydroxyvitamin D 3 [3] [4] [5] , and TGF- [6] induce DC with tolerogenic properties in vitro. These DC are generally characterized by an immature or semimature phenotype, with low expression of costimulatory molecules. In addition, tolerogenic DC produce low amounts of proinflammatory cytokines and high amounts of anti-inflammatory cytokines.
Interactions between DC and regulatory T cells (Treg) facilitate the immunosuppression, immature DC induce Treg, and vice versa Treg prepare DC to become immunosuppressive [7, 8] .
The biological active form of vitamin D is mediated by the active hormonal form 1 ,25-dihydroxyvitamin D 3 (hereafter referred to as vitamin D 3 ). Its intracellular transcriptional effects are mediated through binding to the vitamin D receptor (VDR), which subsequently functions as a transcription factor. VDR is constitutively expressed in APC, such as macrophages and DC, and is inducible in activated T lymphocytes [9] [10] [11] .
Several studies have demonstrated immunosuppressive effects of vitamin D 3 on the functions of DC. In vitro maturation of both human and mouse DC in presence of vitamin D 3 lead to reduced expression of MHC-II and the costimulatory molecules CD40, CD80, and CD86 resulting in an enhanced production of IL-10 and a reduced secretion of IL-12 [12, 13] .
Vitamin D 3 deficiency has been associated with a higher rate of several diseases, including multiple sclerosis (MS) [14, 15] . Moreover, administration of vitamin D 3 in the animal model experimental autoimmune encephalitis (EAE) suppressed the development and progression of disease [16] , and vitamin D 3 has also been shown to ameliorate several other models of autoimmune diseases [17, 18] .
Infection with Gram-negative bacteria provides lipopolysaccharide (LPS), which contains pathogen-associated molecular patterns (PAMP) that function as a Toll-like receptor (TLR) ligand. LPS is detected by TLR4 and is one of the major components used for inducing maturation of monocyte-derived DC in vitro [19] . TLR are expressed by many APC and activate an intracellular signaling pathway that leads to transcriptional activation of proinflammatory genes and innate effector molecules [20] .
It is feasible that PAMP and TLR ligands interfere with vitamin D 3 functions in the immune system. This would be consistent with the fact that individuals with severe vitamin D 3 deficiencies have an increase susceptibility to intracellular infections [21] . A recent study shows that the influence of vitamin D 3 on TLR4 ligand-induced activation of APC is dependent on the order of VDR and TLR4 engagement [9] . To further study the interplay between TLR agonists and vitamin D 3 , we examined the maturation and cytokine profile of DC differentiated in vitro from human peripheral blood monocytes.
Materials and Methods

Ethical Approval.
The study was conducted in accordance with the Ethical Declaration of Helsinki. The project was approved by the local Ethics Committee on Biomedical Research Ethics (j. no20090210).
Isolation of Peripheral Blood Mononuclear Cells.
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats (Blood bank, Aarhus University Hospital, Skejby, Denmark) of healthy donors using Ficoll-Paque PLUS (GE Healthcare BioScience AB, Uppsala, Sweden) with density gradient centrifugation according to the manufacturer's procedure. PBMC were cryopreserved in 90% heat-inactivated fetal bovine serum (FBS) (Sigma-Aldrich, Saint Louis, USA) supplemented with 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Saint Louis, MO, USA) at a concentration of 10 7 cells/mL and stored at −80 ∘ C until use. ∘ C. Finally, the suspension was placed into the EasySep Magnet, and the desired negatively selected untouched monocytes were collected. To increase purity, the magnetic isolation procedure was repeated once, and the harvested cells were kept cold. The purity of the untouched monocytes was evaluated by flow cytometry for CD14 expression. Cells were collected and labeled with FITC-conjugated mouse anti-CD14 monoclonal antibody (TÜK4, DAKO Denmark A/S, Glostrup, Denmark). Cell populations were analyzed on a Cytomics FC500 flow cytometer (Beckman-Coulter) and with FlowJo software (Tree Star, Ashland, USA). The purity ranged from 85 to 95% (data not shown).
Isolation of CD14
Generation of Monocyte-Derived Dendritic Cells.
The purified monocytes were washed twice and cultured in 6-well plates (Techno Plastic Products) at a density of 0.5-0.7 × 10 6 cells/mL in 1.2 mL of RPMI 1640 medium (Gibco, LifeTechnologies, UK) supplemented with 2% normal human serum type AB (NHS AB), 2 mM glutamine, and 20 g/mL gentamicin (Gibco). The cultures were established in the presence of 100 ng/mL recombinant human GM-CSF (Bayer Healthcare AG, Leverkusen, Germany or Peprotech, London, UK) and 20 ng/mL recombinant human IL-4 (Immunotools GmbH, Friesoythe, Germany). The plates were incubated at 37 ∘ C with 5% CO 2 for six days. On day 3, the cultures were supplemented with 360 L fresh medium supplemented with 100 ng/mL GM-CSF and 20 ng/mL IL-4. On day 5, 1.56 mL fresh medium supplemented with 100 ng/mL GM-CSF and 20 ng/mL IL-4 was added to the cultures together with 0, 20, or 100 nM of 1 ,25-dihydroxyvitamin D 3 (Sigma-Aldrich) as indicated. On day 6, either mock (medium), bacterial LPS (E. coli O111:B4, LPS ultrapure cat. no. tlrl-3pelps, InvivoGen, San Diego, USA) in concentrations of 0, 0.01, 0.1, 1, 10, or 100 ng/mL, or PGN (from S. aureus, cat. no. tlrl-pgnsa, InvivoGen) in concentrations of 0, 0.1, 0.5, 1, 5, or 10 g/mL was added during the last 24 hrs of culture. On day 7, all supernatants were collected and frozen at −70 ∘ C and all cells were harvested for subsequent phenotypic and functional analyses.
Morphological Examination.
In order to examine the morphological maturation of the cells, viability and morphology were evaluated by light microscopy (Leica Microsystems) of the cells in the 6-well plates at a magnification of ×10 or ×40 prior to harvest. 
Flow Cytometric
Western Blotting Analysis/Cell Lysis and Immunoblotting.
Whole-cell extracts were prepared using 1x lysis buffer (Cell Signaling Technology, Beverly, MA, USA) supplemented with 1 mM PMSF, 5 mM NaF, and Complete Mini Protease Inhibitor (Roche Diagnostics, Basel, Switzerland) at a concentration recommended by the manufacturer. Lysates were centrifuged at 2.600 ×g for 5 min, followed by 20.000 ×g for 10 min, and whole-cell extracts were immediately frozen at −70 ∘ C. Proteins were separated in XT Criterion 12% gels (BioRad Laboratories Inc, Hercules, CA, USA) using XT MOPS running buffer (Bio-Rad) for 1 h and 30 min at 175 V and subsequently transferred to nitrocellulose membranes for 1 h and 45 min at 300 mA. Detection of VDR was performed using anti-VDR mAb (sc-13133) (Santa Cruz Biotechnology Inc, Dallas, TX, USA) diluted 1 : 1000, and GAPDH was detected using anti-GAPDH antibody (Santa Cruz Biotechnology) diluted 1 : 2000. The secondary antibodies were horseradish peroxidase-conjugated rabbit antimouse or swine anti-rabbit antibody (Dako) diluted 1 : 2000. All antibodies were diluted in 5% skimmed milk in TBS with 0.1% Tween-20. Ponceau-S staining was performed as a loading control. Immunoblots were developed using Super Signal West Femto Maximum Sensitivity Substrate (Thermo Scientific, Rockford, IL, USA).
Results
LPS Induces Rapid Maturation of DC, Which Is
Inhibited by Vitamin D 3 . As expected, vitamin D 3 added 24 hrs prior to LPS treatment inhibited LPS-induced maturation measured by the expression of surface molecules 24 hrs after the addition of LPS (Figure 1(a) ). Conversely, vitamin D 3 prevented the downregulation of CD14 expression, indicating a block in maturation of immature DC (Figure 1(a) ). To further explore the kinetics, cells were examined 4 hrs after addition of LPS. In the absence of vitamin D 3 , DC had already upregulated CD83 and downregulated CD14 after 4 hrs of LPS treatment, whereas only minor or no changes were observed for HLA-DR, CD80, CD86, and CD40. Thus, upregulation of CD83 appears to be an early event during DC maturation. The presence of vitamin D 3 partially inhibited upregulation of CD83 almost to the same degree as observed after 24 hrs.
The early induction of DC maturation was morphologically visible as dendritic formations as early as 4 hrs after the addition of LPS, but more pronounced after 24 hrs. The presence of vitamin D 3 inhibited the outgrowth of these processes (Figure 1(b) ). (Figures 2(a)-2(c)) . Importantly, at low doses of LPS, cytokines were only induced in the presence of vitamin D 3 , despite the fact that neither LPS alone nor vitamin D 3 alone induced measurable cytokines. These data demonstrated that vitamin D 3 acted in synergy with LPS to induce the secretion of IL-6, IL-8, and IL-10.
Vitamin D
Vitamin D 3 Inhibits LPS-Induced IL-12 Secretion.
Since vitamin D 3 is thought to inhibit the proinflammatory response, we next examined whether IL-12, a cytokine that promotes a Th1-like response, was affected by vitamin D 3 . The presence of LPS at concentrations above 1 ng/mL induced high levels of IL-12p70 (Figure 2(d) ). In the presence of either 20 or 100 nM vitamin D 3 , the detection of LPS-induced IL-12p70 was completely abolished. This demonstrated that vitamin D 3 is a potent inhibitor of IL-12.
Vitamin D 3 Is Necessary for PGN-Induced Secretion of IL-6, IL-8, and IL-10.
To test whether LPS was the only TLR ligand able to induce cytokines and act in synergy with vitamin D 3 , differentiated DC were treated with the TLR2 agonist PGN. PGN was able to induce high levels of IL-8 and low levels of IL-6 and IL-10 at high concentrations of PGN (Figures 3(a)-3(c) ). However, in the presence of vitamin D 3 , PGN-induced cytokine secretion from differentiated DC was synergistically increased for IL-6, IL-8, and IL-10 ( Figures 3(a)-3(c) ). In contrast to LPS, PGN did not induce IL-12 ( Figure 3(d) ). This indicated that PGN, similar to LPS, induced cytokine secretion from DC in synergy with vitamin D 3 .
LPS and PGN Enhance Expression of the Vitamin D
Receptor. Vitamin D 3 exerts its function after binding to an intracellular receptor, VDR. To examine whether LPS could increase the sensitivity of DC for vitamin D 3 , the protein level of VDR was measured by western blotting. In the absence of vitamin D 3 or TLR agonists, a low level of VDR was detectable (Figure 4) . However, the presence of LPS or PGN increased the level of VDR, which was not further affected by the presence of vitamin D 3 (Figure 4 ). This indicated that LPS or PGN was able to enhance the sensitivity of DC for vitamin D 3 by increasing the expression of its receptor.
Discussion
The generation of Treg is in part controlled by the maturation of DC. In mice, treatment with vitamin D 3 induces a regulatory T-cell profile with increased expression of IL-10, TGF-, FoxP3, and CTLA-4 and a significant reduction of IL-12p70, IL-23p19, IL-6, and IL-17 [22] . We also observed that vitamin D 3 promoted a regulatory profile, promoting IL-10 and inhibiting IL-12p70. Surprisingly, we found that in synergy with LPS or PGN, vitamin D 3 increased IL-6 in cultures of differentiated DC. Whether the detection of IL-6 indicates a pro-or an anti-inflammatory profile is, however, not clear. IL-6 may be associated with a soluble form of the IL-6 receptor and this complex may mediate proinflammatory reactions through a process known as transsignaling [23] . Blockade of IL-6 transsignaling completely protected gp130 F/F knock-in mutant mice from LPS hypersensitivity, suggesting cross-talk between JAK/STAT and TLR pathways [24] . On the other hand, the classical binding of IL-6 to gp130/IL-6 receptor complexes on the cell surface may promote anti-inflammatory/regenerative reactions [23] . Thus, further investigations may elucidate which one of these scenarios is supported by vitamin D 3 .
Importantly, we found that, at very low levels of LPS, vitamin line of defense against intruding bacteria. This emphasizes that besides its effect on the adaptive immune system, vitamin D 3 also has important functions for the innate immune response. IL-8 has previously been shown to be induced by the transformed cell line THP-1 in the presence of vitamin D 3 and agonists of TLR2, TLR3, TLR4, NOD1, and NOD2 [25] . However, other studies have reported that vitamin D 3 inhibited IL-8 production in response to IL-1 in human peripheral blood mononuclear cells, keratinocytes, and fibroblasts [26, 27] , although TLR and IL-1R are both signals through MyD88. Inhibition of IL-8 by vitamin D 3 has also been observed in primary cultures of human periodontal ligament cells stimulated with P. gingivalis, a Gram-negative bacteria containing LPS [28] . Thus, the cell type, the presence of other cytokines, and potentially virulence factors from microorganisms may all be important for modulating the control exerted by vitamin D 3 on IL-8 secretion.
Although LPS is frequently used to mature monocytederived human DC, other TLR agonist may serve the same functions. LPS is a component of the outer membrane of the Gram-negative bacterial cell wall, whereas Gram-positive bacteria are characterized by a cell wall containing PGN, a ligand for TLR2. In agreement with the observed functions of LPS, PGN also acted in synergy with vitamin D 3 for the secretion of IL-6, IL-8, and IL-10 but was unable to induce IL-12p70 as did LPS. This indicates that PGN from Gram-positive bacteria may also have the ability to prime the response towards a regulatory T-cell profile and that PGN also induces chemoattractants for recruiting polymorphonuclear leukocytes. The level of VDR in part determines the sensitivity of DC for vitamin D 3 . Liu et al. found that the M. tuberculosisderived lipopeptide, which is a TLR2/1 ligand, induced the expression of VDR. In addition, they observed that vitamin D 3 upregulated the antimicrobial peptide cathelicidin, which is important for the killing of intracellular bacteria [19] . However, since most bacteria are extracellular, we examined the general Gram-negative and Gram-positive TLR ligands: LPS (TLR4) and PGN (TLR2). We found that these TLR ligands were also able to increase the level of VDR. The shifting by vitamin D 3 of the immune response towards a regulatory profile as opposed to a proinflammatory response may be of benefit for the invading microorganisms. In this view, the upregulation of VDR by both LPS and PGN may further enhance the effect of vitamin D 3 and thus further prevent the antimicrobial defense. The inhibition of IL-8 induction by P. gingivalis [28] , as mentioned previously, further indicates that the microorganism may have evolved mechanisms to avoid part of these host innate responses. Whether this is a general feature remains to be investigated. Conversely, we speculate that these effects of vitamin D 3 may also prevent unnecessary inflammatory reactions towards commensal microorganisms present in the gut. The shifting towards a regulatory profile by vitamin D 3 may also be of benefit during graft-versus-host disease (GVHD) [29] . However, whether the anti-inflammatory actions of vitamin D 3 can be enhanced in an in vivo setting by the addition of low levels of TLR agonists remains to be examined. The levels of VDR protein in DC were measured by the western blotting of whole-cell lysates from DC cultures stimulated with either mock, 10 ng/mL LPS, or 10 g/mL PGN in the absence or presence of 100 nM vitamin D 3 . GAPDH was used as a loading control. (b) The band intensity in (a) was quantified and normalized to GAPDH as a VDR/GAPDH ratio (VDR expression).
Conclusions
In conclusion, human DC maturation is inhibited by vitamin D 3 . LPS and PGN (TLR4 and TLR2 agonists) increase the level of VDR and act in synergy with vitamin D 3 for induction of IL-6, IL-8, and IL-10, whereas LPS induction of IL-12 is inhibited by vitamin D 3 . PGN does not induce measurable IL-12. Thus, vitamin D 3 synergizes with TLR agonists in modulating human DC cytokine secretion during maturation. This may generate an anti-inflammatory environment that favors the induction of regulatory cells.
